Dermatitis News and Research

Latest Dermatitis News and Research

Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

In rare cases, patients with allergies to metals develop persistent skin rashes after metal devices are implanted near the skin. New research suggests these patients may be at increased risk of an unusual and aggressive form of skin cancer.

10 Oct 2014

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

A study conducted in more than 100 Mongolian schoolchildren found that daily treatment with a vitamin D supplement significantly reduced the symptoms of winter-related atopic dermatitis, a type of eczema.

5 Oct 2014

Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Itch. Scratch. Repeat. Irritating skin conditions, such as seborrheic dermatitis (SD), can create a distracting, uncomfortable vicious circle for those affected.

1 Oct 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Belgian receives research grant from Jeffrey Modell to help cure IPEX syndrome

For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory. The team of Adrian Liston from VIB-KU Leuven will use the grant to develop a gene therapy to cure children that suffer from IPEX syndrome, a rare and fatal autoimmune disorder in which the immune system attacks the body's own tissues and organs.

9 Sep 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.

25 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

Dermatologist warns about safety of children's skin care products

Before the advent of Internet search engines, parents obtained much of their medical advice from their child's doctor.

8 Aug 2014

Study: Nervous system and stress affect inflammatory skin conditions

Anyone who's had a pimple form right before an important event may wonder if stress caused the break out.

7 Aug 2014

UCSF study: Acute psychological stress promotes healing in mouse models of different skin irritations

Brief, acute psychological stress promoted healing in mouse models of three different types of skin irritations, in a study led by UC San Francisco researchers.

7 Aug 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils.

19 Jul 2014

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Scientists funded by the National Institutes of Health have identified genetic markers associated with eosinophilic esophagitis (EoE), an inflammatory disease characterized by high levels of immune cells called eosinophils in the esophagus.

15 Jul 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

10 Jul 2014

Study gives parents, doctors new options to treat children with eczema

The number of children with atopic dermatitis, often referred to as eczema, is on the rise. Some estimate that one in five children in the U.S. now suffers from the painful, itchy skin condition. In an effort to control their symptoms, many children are prescribed powerful medications like immunosuppressants or topical steroids.

9 Jul 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care.

9 Jun 2014

Dermatitis News and Research

Latest Dermatitis News and Research

Chronic contact allergy from metal orthopedic implant linked to aggressive form of skin cancer

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

Mission Pharmacal adds Ovace Plus Lotion to its range of product offerings

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

EYLEA Injection gets approval in Japan for treatment of myopic CNV

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Belgian receives research grant from Jeffrey Modell to help cure IPEX syndrome

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Dermatologist warns about safety of children's skin care products

Study: Nervous system and stress affect inflammatory skin conditions

UCSF study: Acute psychological stress promotes healing in mouse models of different skin irritations

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

NIH-funded study identifies genetic markers associated with eosinophilic esophagitis

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Study gives parents, doctors new options to treat children with eczema

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Celsus’ expert highlights serious side effects of topical corticosteroids

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Dermatitis News and Research

Latest Dermatitis News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in